PH-responsive theranostic polymer-caged nanobins: Enhanced cytotoxicity and T1 MRI contrast by Her2 targeting

Bong Jin Hong, Elden P. Swindell, Keith W. MacRenaris, Patrick L. Hankins, Anthony J. Chipre, Daniel J. Mastarone, Richard W. Ahn, Thomas J. Meade, Thomas V. O'Halloran, Sonbinh T. Nguyen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

A polymer-caged nanobin (PCN) theranostic platform with a doxorubicin (DXR)-loaded liposomal core and an acid-sensitive polymer shell that is functionalized with herceptin and GdIII-based magnetic resonance imaging (MRI) contrast agents is reported. In vitro testing reveals an 120-fold improvement in cellular GdIII uptake in comparison with clinically approved DOTA-GdIII, leading to significant T1 MRI contrast enhancement.

Original languageEnglish (US)
Pages (from-to)770-774
Number of pages5
JournalParticle and Particle Systems Characterization
Volume30
Issue number9
DOIs
StatePublished - Sep 2013

Keywords

  • cancer targeting
  • drug delivery
  • magnetic resonance imaging
  • pH-responsive drug release
  • theranostics

ASJC Scopus subject areas

  • Chemistry(all)
  • Materials Science(all)
  • Condensed Matter Physics

Fingerprint Dive into the research topics of 'PH-responsive theranostic polymer-caged nanobins: Enhanced cytotoxicity and T<sub>1</sub> MRI contrast by Her2 targeting'. Together they form a unique fingerprint.

Cite this